Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115488004> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W3115488004 endingPage "1309" @default.
- W3115488004 startingPage "1309" @default.
- W3115488004 abstract "1309 Objectives: 131I-Hyp serves a powerful radiopharmaceutical against solid tumours when it was concomitantly used with a vascular disrupting agent (VDA), which was named as the sequential dual-targeting theragnostic strategy (SDTTS) or Oncocidia. However, poor hydrophilicity of both Hypand 131I-Hyp has always been an obstacle for its clinical application. We were committed to finding a legal preparation (Hydroxypropyl β-cyclodextrin, HP-β-CD) for 131I-Hyp/Hyp to replace their traditional preparation (with lots of DMSO) for intravenous injection.Materials and Methods: solubility of Hyp in HP-β-CD solution was evaluated by UV spectrophotometry and 50% HP-β-CD was chosen as the main solvent. 131I-Hyp was labelled from 1 mg/mL Hyp in the traditional preparation (contained 30% DMSO), the improved preparation 1 (contained 50% HP-β-CD), and the improved preparation 2 (contained 6% DMSO with 50% HP-β-CD) , i.v. injected at the dosage of 3.96 MBq/kg of 131I in rats (N=6/group) with liver and muscle necrosis. Tissues were sampled after 24 hr for gamma counting, autoradiography and H&E staining. Results: No preparation was be labelled with 131I, and 131I-Hyp exhibited radiochemical purity above 90% in the preparations. Hyp solubility was enhanced with increasing HP-β-CD, and higher than 1 mg/mL in the solvents higher than 40% HP-β-CD. The targetability of 131I-Hyp did not changed in the improved preparations, necrotic liver exhibited higher radioactivity, blue-stained by EB and lower hematoxylin dye on H&E staining. The radioactivity cleaned fast in blood in the improved preparations. Conclusions: The improved preparations contained HP-β-CD could be a suitable pharmaceutical excipient for i.v. injection of 131I-Hyp solution." @default.
- W3115488004 created "2021-01-05" @default.
- W3115488004 creator A5044367029 @default.
- W3115488004 date "2020-05-01" @default.
- W3115488004 modified "2023-09-23" @default.
- W3115488004 title "Hydroxypropyl β-cyclodextrin as the pharmaceutical excipient for radioiodinated hypericin improves solubility and plasma clearance without affecting netrotic targeting." @default.
- W3115488004 hasPublicationYear "2020" @default.
- W3115488004 type Work @default.
- W3115488004 sameAs 3115488004 @default.
- W3115488004 citedByCount "0" @default.
- W3115488004 crossrefType "journal-article" @default.
- W3115488004 hasAuthorship W3115488004A5044367029 @default.
- W3115488004 hasConcept C13965031 @default.
- W3115488004 hasConcept C142724271 @default.
- W3115488004 hasConcept C155574463 @default.
- W3115488004 hasConcept C178790620 @default.
- W3115488004 hasConcept C185592680 @default.
- W3115488004 hasConcept C2778432610 @default.
- W3115488004 hasConcept C2780471494 @default.
- W3115488004 hasConcept C43617362 @default.
- W3115488004 hasConcept C55493867 @default.
- W3115488004 hasConcept C71924100 @default.
- W3115488004 hasConcept C74864618 @default.
- W3115488004 hasConcept C98274493 @default.
- W3115488004 hasConceptScore W3115488004C13965031 @default.
- W3115488004 hasConceptScore W3115488004C142724271 @default.
- W3115488004 hasConceptScore W3115488004C155574463 @default.
- W3115488004 hasConceptScore W3115488004C178790620 @default.
- W3115488004 hasConceptScore W3115488004C185592680 @default.
- W3115488004 hasConceptScore W3115488004C2778432610 @default.
- W3115488004 hasConceptScore W3115488004C2780471494 @default.
- W3115488004 hasConceptScore W3115488004C43617362 @default.
- W3115488004 hasConceptScore W3115488004C55493867 @default.
- W3115488004 hasConceptScore W3115488004C71924100 @default.
- W3115488004 hasConceptScore W3115488004C74864618 @default.
- W3115488004 hasConceptScore W3115488004C98274493 @default.
- W3115488004 hasLocation W31154880041 @default.
- W3115488004 hasOpenAccess W3115488004 @default.
- W3115488004 hasPrimaryLocation W31154880041 @default.
- W3115488004 hasRelatedWork W1969092440 @default.
- W3115488004 hasRelatedWork W1969207169 @default.
- W3115488004 hasRelatedWork W2000181178 @default.
- W3115488004 hasRelatedWork W2048194104 @default.
- W3115488004 hasRelatedWork W2063920255 @default.
- W3115488004 hasRelatedWork W2079459039 @default.
- W3115488004 hasRelatedWork W2086540068 @default.
- W3115488004 hasRelatedWork W2088336598 @default.
- W3115488004 hasRelatedWork W2092475296 @default.
- W3115488004 hasRelatedWork W2118606589 @default.
- W3115488004 hasRelatedWork W2171461624 @default.
- W3115488004 hasRelatedWork W2197714561 @default.
- W3115488004 hasRelatedWork W2562600781 @default.
- W3115488004 hasRelatedWork W2801159867 @default.
- W3115488004 hasRelatedWork W2914540748 @default.
- W3115488004 hasRelatedWork W2991354377 @default.
- W3115488004 hasRelatedWork W3131104945 @default.
- W3115488004 hasVolume "61" @default.
- W3115488004 isParatext "false" @default.
- W3115488004 isRetracted "false" @default.
- W3115488004 magId "3115488004" @default.
- W3115488004 workType "article" @default.